A Phase 3 interventional study of Liposomal Cyclosporine A and Standard of Care in Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant and Lung Transplant Rejection, sponsored by Zambon SpA. Completed at 40 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Zambon SpA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Bronchiolitis Obliterans with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Bronchiolitis Obliterans · United States.
Among the 34 studies in Bronchiolitis Obliterans with a site in United States, this one is the 2nd largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 3, and was the 22nd registered.
82 studies on the registry are indexed under Bronchiolitis Obliterans; 9 are open to participants now.
Browse Bronchiolitis Obliterans studies →5 of the 34 studies in Bronchiolitis Obliterans with a site in United States are open now. Recruiting first, the newest first:
Brian Keller · Sites in United States
Ages 7+
Deciphera Pharmaceuticals, LLC · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages up to 24
M.D. Anderson Cancer Center · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Bronchiolitis Obliterans studies recruiting now, 5 set no upper age limit and 4 stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 5 · Phase 4 1
First in 2001; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 169 is above the median of 26 across 57 interventional studies indexed under Bronchiolitis Obliterans.
Median enrollment 19 across the 25 interventional studies, 220 across the 7 observational. Of the 27 that completed or were terminated, 10 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 34 have an industry lead sponsor. The 10 most frequent:
Zambon SpA is the lead sponsor of 23 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Zambon SpA has 3 studies filed under Bronchiolitis Obliterans — fewer than ten, so there is no comparison to draw.
1 of the studies in Bronchiolitis Obliterans with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05922761Dana-Farber Cancer InstituteBElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Bronchiolitis Obliterans with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this trial was to assess the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) as add-on therapy to standard of care (SoC) as compared to SoC alone in double lung transplant (DLT) recipients with chronic lung allograft dysfunction (CLAD)-bronchiolitis obliterans syndrome (BOS).
This was a Phase III, open-label, prospective, multicenter, randomized, controlled clinical trial of L-CsA for the treatment of BOS in adults following DLT. The patient population was recipients of a double pulmonary allograft, > or = 18 years old, with clinically defined CLAD--BOS with screening FEV1 >or = 51% of personal best FEV1 value post-transplant during the Screening period.
The rationale for an open-label study was driven by concerns that a sucrose-containing placebo formulation could increase a potential risk of pulmonary infection without the benefit of L-CsA. Sucrose is a lyoprotectant in the manufacturing process. After carefully considering alternative options for lyoprotection, no sugar-free alternatives that would qualify as a real placebo (i.e., undistinguishable by means of appearance, taste, or smell) could be identified.
Therefore, an open-label, randomized controlled trial versus SoC was the only suitable alternative.
An open-label clinical trial generally bears the potential for bias in patient treatment and care, and thus trial outcome. However, for this trial the risk of bias is considered low because of the following reasons:
Stratification prior to randomization was performed to limit imbalances between treatment arms with respect to key variables and potential confounders.
There were major recruitment issues in both the BOSTON-1 trial (SLT recipients) and the present BOSTON-2 trial, in part due to Coronavirus disease-2019 (COVID-19) and specifically in BOSTON-1 due to a marked decline over time in the use of SLT. Following FDA recommendation to obtain an adequately sized safety database for inhaled L-CsA and reach the originally planned sample size for BOSTON-1 and BOSTON-2 trials combined, it was planned to stop randomization into the two Phase III clinical trials upon achievement of a combined total of approximately 220 patients, of which approximately 160 to 170 patients were planned for enrollment in BOSTON-2. To assure balance between treatment arms with regard to key variables and potential confounders, stratification prior to randomization was performed. Within each of the 8 strata, using a permuted blocks randomization, patients were randomly assigned with equal probability (1:1) to receive either L-CsA (10 mg) via the PARI eFlow Nebulizer System twice daily (BID) plus SoC treatment or SoC alone, for a period of 48 weeks. Patients were monitored every 4 to 8 weeks over 48 weeks for efficacy parameters and for all safety evaluations. All patients were eligible to continue in an open-label extension trial of L-CsA, BOSTON-3 (Study BT-L-CsA-303-FU) following completion of either BOSTON-1 or BOSTON-2.
Up to 11 visits (Screening, V1 through V10) were planned during the clinical trial. After informed consent had been obtained, a Screening Visit was carried out to check general eligibility for participation. At the Baseline Visit (V1, Randomization Visit), inclusion and exclusion criteria were re-checked, and Baseline serial spirometry was performed. During the 48-week treatment period, visits were scheduled every 4 to 8 weeks (V2 to V9). Visit 9 (End of Treatment [EoT) was scheduled to occur 48 weeks after Visit 1. If a patient had an event that met the first criterion for progression of BOS, progression of BOS must have been confirmed by measurements that were taken with COMPACT spirometer at least 2 weeks apart. Visit 10 (EoS) was a safety follow-up visit performed 4 weeks after Visit 9/EoT only in patients not rolling over to the extension study (BOSTON-3). For patients who rolled over to BOSTON-3, the EoT Visit was the EoS Visit. Every effort was made to have all planned and unscheduled visits at the study site. However, if one of the visits from Visit 2 to Visit 8 and discontinuation visits could not be performed at the site due to COVID-19, remote visits (e.g., by telephone) were possible. Mandatory on-site visits were Screening Visit, Visit 1, and Visit 9.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who met the following criteria as stated in the protocol were included in the study:
Patients with BOS diagnosis defined as CLAD-BOS phenotype with:
Diagnosis of CLAD-BOS must have been made at least 12 months after lung transplantation and
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liposomal Cyclosporine A (L-CsA) 10 mg twice daily for 48 weeks, plus Standard of Care Therapy
Drug: Liposomal Cyclosporine A
This is a maintenance regimen of immunosuppressive agents
Drug: Standard of Care
This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm. The L-CsA was administered as 10 mg/2.4 mL inhalation via the PARI eFlow device BID (morning/evening, approximately 12 hours apart) for 48 weeks. Nebulization time per inhalation dose was approximately 6 to 17 minutes. Patients received training on the use of the device and the first dose of L-CsA was self-administered by each patient under the supervision of trained personnel. In addition, during all subsequent scheduled visits the L-CsA inhalation was self-administered by the patient and under the supervision of trained study personnel.
Also known as: L-CsA
Standard of Care Therapy (SoC). The SoC included maintenance immunosuppressive medication including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent; but also a prophylaxis against common opportunistic infections, and all other necessary medications and therapies for the optimal care of the patient. This also included vaccination against COVID-19 All changes in concurrent treatment or medication were administered according to site's SoC. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, should be on a stable regimen for a least 4-weeks prior to randomization and continued to receive azithromycin during the trial as deemed appropriate by the investigator.
Also known as: SoC
Mean Change in FEV1 (Liters) From Baseline to Week 48
FEV1 is the Forced Expiratory Volume in One Second. The FEV1 data collected from the on-site COMPACTTM spirometer were to be considered primary, while data collected with the In2itiveTM home spirometer were to be used for supportive analyses.
Time frame: Week 48
Mean Change in FEV1/ Forced Vital Capacity (FVC) From Baseline to Week 48
Forced Expiratory Volume in One Second on Forced Vital Capacity. It was analysed in the FAS using a LMM for repeated measurements, with baseline FEV1/FVC among covariates. In case of death or re- transplantation events, FEV1/FVC was imputed as zero at each nominal day post event. FEV1/FVC is a calculated ratio used to diagnose obstructive and restrictive lung disease. It represents the proportion of a patient's vital capacity that he/she is able to expire in the first second of forced expiration to the full forced vital capacity.
Time frame: Week 48
Time to Progression of Bronchiolitis Obliterans Syndrome (BOS)
Time to progression of BOS, defined as the earliest of the following: * Absolute decrease from Baseline in FEV1 ≥10% or ≥ 200 mL (0.2 L) and absolute decrease in FEV1/FVC of \> 5% OR * Worsening of BOS grade, OR * Re-transplantation, OR * Death from respiratory failure. More than one type of event might correspond to the event of BOS progression (even those occurring on the same date). In case progression of BOS was defined by more than one criterion on different dates, the earliest event date was considered, i.e., the date closer to randomization was used as the progression date.
Time frame: From date of randomization until the date of first documented progression of BOS, or date of retransplantation, or date of death from respiratory failure, whichever came first, assessed up to 48 weeks.
Acute Tolerability of L-CsA: FEV1 Change From Pre-dose to 1 Hour and 4 Hours Post-dose
Acute tolerability of IMP (L-CsA) during initial dosing was determined by measuring spirometry 1 hour and 4 hours after treatment. The FEV1 was measured prior to dosing with L-CsA. A decline of ≥20% associated with symptoms could have warranted IMP discontinuation. Parameters reflecting acute tolerability of IMP were: spirometry, cough, or dyspnea.
Time frame: Pre-dose and 1- and 4-hours post-dose on Visit 1
Count of Participants With at Least One Adverse Event (AE)
An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine.
Time frame: Baseline through study completion (52 weeks)
The COVID-19 pandemic impacted the conduct of the study. Based on the evolution of the outbreak and in accordance with country- and site-specific determinations, recruitment was put on hold starting on 20 March 2020. Recruitment was subsequently resumed in Quarter 3 2020. COVID- 19 might have affected the results for different reasons including changes in infection rate and type, quarantining, social distancing, and other considerations linked to different ways each site managed the pandemic.
| Milestone | L-CsA Treatment Plus SoC | Standard of Care |
|---|---|---|
| Started | 84 | 85 |
| Full analysis set | 84 | 85 |
| Safety analysis set | 84 | 85 |
| Per protocol set | 46 | 70 |
| Completed | 69 | 79 |
| Not completed | 15 | 6 |
| Withdrew: Adverse event | 5 | 4 |
| Withdrew: Withdrawal by subject | 7 | 2 |
| Withdrew: Screen fail after randomization | 1 | 0 |
| Withdrew: Pi decision due to patient condition | 1 | 0 |
| Withdrew: Patient unresponsiveness | 1 | 0 |
FEV1 is the Forced Expiratory Volume in One Second. The FEV1 data collected from the on-site COMPACTTM spirometer were to be considered primary, while data collected with the In2itiveTM home spirometer were to be used for supportive analyses.
| Liters | L-CsA Treatment Plus SoC - FAS | Standard of Care - FAS |
|---|---|---|
| Mean Change in FEV1 (Liters) From Baseline to Week 48 | -0.096 ± 0.1120 | -0.067 ± 0.1147 |
Forced Expiratory Volume in One Second on Forced Vital Capacity. It was analysed in the FAS using a LMM for repeated measurements, with baseline FEV1/FVC among covariates. In case of death or re- transplantation events, FEV1/FVC was imputed as zero at each nominal day post event. FEV1/FVC is a calculated ratio used to diagnose obstructive and restrictive lung disease. It represents the proportion of a patient's vital capacity that he/she is able to expire in the first second of forced expiration to the full forced vital capacity.
| ratio | L-CsA Treatment Plus SoC - FAS | Standard of Care - FAS |
|---|---|---|
| Mean Change in FEV1/ Forced Vital Capacity (FVC) From Baseline to Week 48 | -0.100 ± 0.0722 | -0.083 ± 0.0702 |
Time to progression of BOS, defined as the earliest of the following: * Absolute decrease from Baseline in FEV1 ≥10% or ≥ 200 mL (0.2 L) and absolute decrease in FEV1/FVC of \> 5% OR * Worsening of BOS grade, OR * Re-transplantation, OR * Death from respiratory failure. More than one type of event might correspond to the event of BOS progression (even those occurring on the same date). In case progression of BOS was defined by more than one criterion on different dates, the earliest event date was considered, i.e., the date closer to randomization was used as the progression date.
| weeks | L-CsA Treatment Plus SoC - FAS | Standard of Care - FAS |
|---|---|---|
| Time to Progression of Bronchiolitis Obliterans Syndrome (BOS) | NA (NA to NA) | NA (NA to NA) |
Acute tolerability of IMP (L-CsA) during initial dosing was determined by measuring spirometry 1 hour and 4 hours after treatment. The FEV1 was measured prior to dosing with L-CsA. A decline of ≥20% associated with symptoms could have warranted IMP discontinuation. Parameters reflecting acute tolerability of IMP were: spirometry, cough, or dyspnea.
| Liters | L-CsA Treatment Plus SoC - SAF |
|---|---|
| 1h post-dose | -0.019 ± 0.0855 |
| 4h post-dose | -0.005 ± 0.0914 |
An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine.
| Participants | L-CsA Treatment Plus SoC - SAF | Standard of Care SAF |
|---|---|---|
| with any TEAE | 73 | 77 |
| with any TEAE Leading to discontinuation of study treatment | 12 | 0 |
| with any TEAE Leading to study discontinuation | 5 | 3 |
| with any TEAE Leading to death | 2 | 4 |
| with any TEAE mild | 66 | 68 |
| with any TEAE moderate | 50 | 56 |
| with any TEAE severe | 21 | 18 |
| with any study treatment-related TEAE | 39 | 0 |
| with any serious TEAE | 46 | 44 |
Collected over From baseline throughout the study, till week 52.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| L-CsA Treatment Plus SoC - SAF | 2/84 (2.4%) | 46/84 (54.8%) | 73/84 (86.9%) |
| Standard of Care - SAF | 4/85 (4.7%) | 44/85 (51.8%) | 77/85 (90.6%) |
| Event | L-CsA Treatment Plus SoC - SAF | Standard of Care - SAF |
|---|---|---|
| COVID-19Infections and infestations | 23/84 | 21/85 |
| COVID-19 pneumoniaInfections and infestations | 5/84 | 1/85 |
| Acute kidney injuryRenal and urinary disorders | 5/84 | 2/85 |
| BronchitisInfections and infestations | 3/84 | 1/85 |
| GastroenteritisInfections and infestations | 3/84 | 0/85 |
| PneumoniaInfections and infestations | 3/84 | 3/85 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/84 | 3/85 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/84 | 1/85 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/84 | 1/85 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/84 | 1/85 |
| Event | L-CsA Treatment Plus SoC - SAF | Standard of Care - SAF |
|---|---|---|
| COVID-19Infections and infestations | 23/84 | 21/85 |
| CoughRespiratory, thoracic and mediastinal disorders | 19/84 | 7/85 |
| Disease progressionGeneral disorders | 16/84 | 15/85 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/84 | 5/85 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 9/84 | 0/85 |
| BronchitisInfections and infestations | 8/84 | 5/85 |
| DiarrhoeaGastrointestinal disorders | 8/84 | 6/85 |
| HeadacheNervous system disorders | 8/84 | 0/85 |
| NasopharyngitisInfections and infestations | 6/84 | 8/85 |
| Oedema peripheralGeneral disorders | 7/84 | 7/85 |
Full Analysis Set (FAS): The FAS was defined as all randomized patients. Patients were analyzed according to the treatment group to which they were randomized. All primary, secondary and exploratory endpoints were performed using the FAS, unless otherwise specified.
| Age, Categorical(Participants) | L-CsA Treatment Plus SoC - SAF | Standard of Care - SAF | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 58 | 64 | 122 |
| >=65 years | 26 | 21 | 47 |
| Age, Continuous(years) | L-CsA Treatment Plus SoC - SAF | Standard of Care - SAF | Total |
|---|---|---|---|
| Mean | 56.5 ± 12.69 | 56.2 ± 10.82 | 56.3 ± 11.75 |
| Sex: Female, Male(Participants) | L-CsA Treatment Plus SoC - SAF | Standard of Care - SAF | Total |
|---|---|---|---|
| Female | 34 | 42 | 76 |
| Male | 50 | 43 | 93 |
| Ethnicity (NIH/OMB)(Participants) | L-CsA Treatment Plus SoC - SAF | Standard of Care - SAF | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 10 |
| Not Hispanic or Latino | 70 | 71 | 141 |
| Unknown or Not Reported | 8 | 10 | 18 |
| Race (NIH/OMB)(Participants) | L-CsA Treatment Plus SoC - SAF | Standard of Care - SAF | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 5 | 7 |
| White | 75 | 70 | 145 |
| More than one race | 4 | 1 | 5 |
| Unknown or Not Reported | 2 | 8 | 10 |
| Region of Enrollment(participants) | L-CsA Treatment Plus SoC - SAF | Standard of Care - SAF | Total |
|---|---|---|---|
| Austria | 2 | 3 | 5 |
| Belgium | 4 | 2 | 6 |
| United States | 30 | 31 | 61 |
| Denmark | 1 | 3 | 4 |
| United Kingdom | 3 | 3 | 6 |
| Israel | 4 | 1 | 5 |
| France | 4 | 8 | 12 |
| Germany | 15 | 19 | 34 |
| Spain | 21 | 15 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2019 to primary completion in Mar 2024, 59 months.
Results were first posted in Jul 2025, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine